Global Atherosclerosis Therapeutics Market, By Drug Treatment (Anti-Platelet Medications, Cholesterol Lowering Medications, Beta Blockers, Angiotensin-Converting Enzyme (ACE) Inhibitors, Calcium Channel Blockers, Water Pills, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028
Atherosclerosis therapeutics market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market is growing at a CAGR of 6.78% in the above-mentioned research forecast period. Continuous elevation in the prevalence rate of heart attacks owing to atherosclerosis or coronary heart disease across the world anticipated to accelerate the market growth rate.
Moreover, growing geriatric population and increasing awareness regarding heart related diseases also boost up the market growth in the forecast time period. Moreover, increase in per capita income act as opportunity for the market growth. But, sometimes adverse effect associated with Atherosclerosis Therapeutics products such as constipation, dizziness, fast heartbeat (palpitations), fatigue, flushing, headache, and nausea; which may constrict the further market growth pace. Moreover, stringent regulations may hamper the growth of global atherosclerosis therapeutics market.
Arteriosclerosis develops when the blood vessels known as arteries that transport nutrients and oxygen from heart to the all over body become massive and rigid. This stiffness induces restriction of blood flow to other tissues and organs. Whereas, healthy arteries are elastic and flexible, but after the time, the walls of arteries become harden, and induces Arteriosclerosis.
Additionally, growing number initiative activities by healthcare organizations and government bodies anticipated to escalate the future market growth pace. Moreover, growing number of strategies by major market players such as acquisition, partnership, distribution agreement, participation in conference, product introduction and announcement of clinical trial result anticipated to upsurge the market growth pace.
This atherosclerosis therapeutics market provides details of market share, new developments and product pipeline analysis, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions and technological innovations in the market. To understand the analysis and the market scenario contact us for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Global Atherosclerosis Therapeutics Market Scope and Market Size
Atherosclerosis therapeutics market is segmented on the drug treatment, and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of drug treatment, the atherosclerosis therapeutics market is segmented into cholesterol lowering medications, anti-platelet medications, calcium channel blockers, beta blockers, angiotensin-converting enzyme (ACE) inhibitors, water pills, and others.
- On the basis of distribution channel, the atherosclerosis therapeutics market has also been segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy and others.
Atherosclerosis Therapeutics Market Country Level Analysis
Atherosclerosis therapeutics market is analysed and market size information is provided by country, drug treatment, and distribution channel as referenced above.
The countries covered in the atherosclerosis therapeutics market report are U.S., Canada, Mexico in North America, Brazil, Argentina, Peru, Rest of South America, as part of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa, as a part of Middle East and Africa.
North America accounts the largest market share due to the growing healthcare expenditure and rising incidence of coronary heart disease or atherosclerosis. Moreover, growing clinical research activities by major market players anticipated to bolster the market growth. Europe accounts the second largest market share due to increasing disposable income and presence of wide distribution network for atherosclerosis therapeutics. Asia-Pacific is expected to account for the largest market share over coming years for the atherosclerosis therapeutics market due to constant rise in heart disease patient pool and enormous presence of new treatment approaches (branded and generic) in atherosclerosis therapeutics market.
The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
Atherosclerosis therapeutics market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Atherosclerosis Therapeutics Market Share Analysis
Atherosclerosis therapeutics market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related to atherosclerosis therapeutics market.
The major players covered in the atherosclerosis therapeutics market Johnson & Johnson Services, Inc., Cardium Therapeutics, Inc., Bayer AG, Anthera Pharmaceuticals, Inc., Isis Pharmaceuticals, Inc., GlaxoSmithKline plc., F. Hoffmann-La Roche Ltd., Sanofi S.A., AstraZeneca Plc., Merck & Co., Inc., Novartis AG, The Medicine Company, and Cardium Therapeutics, among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
In November 2016, Amgen has announced that adding Repatha (evolocumab) to optimized statin therapy resulted in statistically significant regression of atherosclerosis in patients with coronary artery disease (CAD). This announcement has strengthened company footprints in the market.